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Abstract 
 
Aim Constitutive genetic deletion of the adaptor protein p66
Shc
 was shown to protect from 
ischaemia/reperfusion injury. Here, we aimed at understanding the molecular mechanisms underlying this 
effect in stroke and studied p66
Shc
 gene regulation in human ischaemic stroke.  
Methods and Results Ischaemia/reperfusion brain injury was induced by performing a transient middle 
cerebral artery occlusion surgery on wild-type mice. After the ischaemic episode and upon reperfusion, small 
interfering RNA targeting p66
Shc
 was injected intravenously. We observed that post-ischaemic p66
Shc
 
knockdown preserved blood-brain barrier integrity that resulted in improved stroke outcome, as identified by 
smaller lesion volumes, decreased neurological deficits, and increased survival. Experiments on primary 
human brain microvascular endothelial cells demonstrated that silencing of the adaptor protein p66
Shc
 
preserves claudin-5 protein levels during hypoxia/reoxygenation by reducing nicotinamide adenine 
dinucleotide phosphate oxidase activity and reactive oxygen species production. Further, we found that in 
peripheral blood monocytes of acute ischaemic stroke patients p66
Shc
 gene expression is transiently increased 
and that this increase correlates with short-term neurological outcome.  
Conclusion Post-ischaemic silencing of p66
Shc
 upon reperfusion improves stroke outcome in mice while the 
expression of p66
Shc
 gene correlates with short-term outcome in patients with ischaemic stroke.  
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Translational Perspective 
 
In light of the limited repertoire of therapeutical options available for the treatment of ischaemic stroke, the 
identification of novel potential targets is vital; in this respect, the present study demonstrates that the adaptor 
protein p66
Shc
 holds this potential as an adjunct therapy to thrombolysis. Post-ischaemic silencing of p66
Shc
 
protein yielded beneficial effects in a mouse model of ischaemia/reperfusion brain injury underlying an 
interesting translational perspective for this target protein. Further, in proof-of-principle clinical experiments 
using peripheral blood monocytes we demonstrate that p66
Shc
 gene expression is transiently increased and that 
its levels correlate to short-term outcome in ischaemic stroke patients. Although these latter experiments are 
not directly relevant to the experiments performed in mice and in human endothelial cells, they provide novel 
important information about p66
Shc
 regulation in stroke patients and set the basis for further investigations 
aimed at assessing the potential for p66
Shc
 to become a novel therapeutic target as an adjunct of thrombolysis 
for the management of acute ischaemic stroke. 
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Introduction 
 
Stroke is associated with major disabilities and mortality
1
. Although over the last decades several novel 
experimental neuroprotective strategies have been developed
2
, their translation into clinical practice has 
proven difficult
3, 4
. Thus, the search for novel therapeutic targets for ischaemic stroke as an adjunct to 
thrombolysis remains an unmet clinical need.  
Although ischaemic stroke is amenable to thrombolysis in patients presenting early after symptom onset
5
, 
vascular leakage and the ensuing oedema formation during reperfusion contributes importantly to neurological 
deficits
6
. Cerebral microvascular endothelial cells are a main component of the blood-brain barrier (BBB)
7
 
which divides the cerebral circulation from brain tissue. These cells are interconnected by tight and adherens 
junction proteins
7
 whose integrity is critical for stroke outcome
8
. Indeed, disruption of the BBB following 
ischaemia/reperfusion (I/R) leads to vascular leakage and infiltration of plasma components into the brain 
tissue leading to oedema and further organ damage
9-11
. Overproduction of reactive oxygen species (ROS) 
following I/R is considered a key mechanism leading to BBB damage
12
. p66
Shc
, an isoform of the mammalian 
adaptor protein Shc
13, 14
, is a crucial mediator of ROS production in several disease states
15-18
 thereby leading 
to cellular apoptosis
19-21
. Indeed, much of the vasculoprotective properties observed by genetic deletion of 
p66
Shc
 in mice are the result of reduced oxidative stress and in turn preserved endothelial function
15-17
.  
In line with the above, we previously demonstrated that mice lacking p66
Shc
 develop smaller stroke size 
following I/R
22
. However, the clinical relevance of this observation remains unknown and the underlying 
molecular mechanisms poorly understood. To this end, we subjected mice to I/R brain injury and, to mimic 
real life clinical conditions as it would occur in the context of thrombolysis, we performed p66
Shc
 silencing in 
vivo using small interfering RNA (siRNA) after the ischaemic episode and upon reperfusion. Additionally, we 
mimicked I/R conditions in primary human brain microvascular endothelial cells (HBMEC) by exposing them 
to hypoxia/reoxygenation (H/R) with and without silencing of p66
Shc
 and assessed the production of ROS as 
well as the levels of tight and adherens junction proteins. Lastly, we studied p66
Shc
 gene expression in 
peripheral blood monocytes (PBM) of patients with acute ischaemic stroke and correlated it to the National 
Institutes of Health Stroke Scale (NIHSS). 
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Methods 
 
Patients 
Twenty-seven patients admitted to the emergency room of San Raffaele Hospital (OSR, Milan, Italy) with a 
diagnosis of acute ischaemic stroke presenting within 6 h from symptom onset were enrolled. Five patients 
presented wake-up stroke and were recruited within 6 h from awakening. The initial diagnosis was based on 
clinical history, neurological examination (conducted by certified neurologists) and a brain computed 
tomography (CT) scan. Nineteen sex- and age-matched healthy volunteers (either relatives or visitors of in-
hospital patients), with a negative history of cardio- and cerebrovascular diseases, were included as controls. 
Patients diagnosed with diabetes, systemic inflammatory diseases, acute infections, and malignancy were 
excluded, to eliminate potential interference of those disease states on p66
Shc
 expression
23
. Blood was 
withdrawn from the antecubital vein at 6 h and 24 h after initial stroke symptoms (for stroke patients), 
whereas control subjects donated blood once. 
Out of the 27 ischaemic stroke patients, 14 received thrombolytic treatment within 4.5 h from initial stroke 
symptoms onset. Ischaemic strokes were clinically classified according to the Oxford Community Stroke 
Project classification (OCSP, also known as the Bamford or OXFORD classification)
24
. Stroke aetiology was 
classified according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria
25
. Moreover, 
stroke severity was assessed, using NIHSS on admission and at discharge. Furthermore, delta NIHSS was 
calculated as the difference between the NIHSS presented at discharge and the NIHSS presented at admission 
(delta NIHSS = NIHSS discharge – NIHSS admission); thereby, positive values indicate short-term 
neurologic worsening while negative values indicate neurological improvement.  
The study was approved by the local Ethics Committee at San Raffaele Scientific Institute, Milan, Italy. All 
participants (or their representative relatives) signed a written informed consent to authorise the treatment of 
their biological and clinical data. 
 
Isolation of peripheral blood monocytes  
PBM from whole-blood were isolated using anti-CD14-coated MicroBeads (Miltenyi Biotec) on a magnetic 
separator (Miltenyi Biotec), as previously described
26
. 
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Animals 
All animal experiments were performed on male, 11-13 weeks old wild-type (wt) (C57/BL6J) mice. Study 
design and experimental protocols were approved by the Cantonal Veterinary Office of the Canton of Zurich.  
 
Middle cerebral artery occlusion (MCAO) 
A transient middle cerebral artery (MCA) occlusion (MCAO) surgery was performed on wt mice to induce I/R 
brain injury, as described
22
. In brief, anaesthesia was induced with 3% isoflurane in oxygen-enriched air and 
mice were kept under 1.5% isoflurane anaesthesia during MCAO surgery. Body temperature was controlled 
by using a warm water heating pad. Incision site was infiltrated with 0.5% bupivacaine solution for pain relief. 
A 6-0 silicone-coated filament (Doccol Corporation) was advanced into the internal carotid artery (ICA) until 
the thread occluded the origin of the left MCA to induce unilateral MCAO. After 45 min (60 min for 
evaluation of long-term effect) of ischaemia, the thread was removed to allow reperfusion of the MCA. After 
wound care and before returning to their standard cage, mice were kept for 1.5 h in a temperature controlled 
cage. For sham operation, the filament was advanced into the ICA without occluding the MCA. 
 
In vivo p66
Shc
 silencing 
In vivo p66
Shc
 silencing was performed as described
27
. Briefly, 1.6 nmol of predesigned siRNA targeting 
p66
Shc
 were incubated with a mixture of 150 mmol/L NaCl solution–jetPEI® and injected intravenously into 
the tail vein of the wt mouse randomized. Scrambled siRNA was used as a negative control. Detailed methods 
are provided in the supplemental material. 
 
Magnetic resonance imaging (MRI) 
Lesion development was monitored after MCAO on a Bruker PharmaScan 47/16 (Bruker BioSpin GmbH) 
operating at 4.7 T. Anaesthesia was induced using 3% isoflurane (Abbott) in a 4:1 air/oxygen mixture. During 
MRI acquisition, mice were kept under isoflurane anaesthesia (1.5%). During the scan session body 
temperature was monitored with a rectal temperature probe (MLT415, ADInstruments) and kept at 36±0.55°C 
7 
 
using a warm water circuit integrated into the animal support (Bruker BioSpin GmbH). MRI recordings were 
done in a blinded way by an independent person.  
The lesion was determined on maps of the apparent diffusion coefficient (ADC) derived from diffusion-
weighted images as areas of significant reduction of the ADC compared to the unaffected, contralateral side. 
The lesion in the T2-weighted image was determined as hyperintense areas compared to the contralateral 
hemisphere. Lesion volumes were quantified blinded by drawing region of interests around the areas of 
reduced ADC and hyperintensities in T2-weighted images in five MRI slices using a ROI tool (Paravision, 
Bruker). Brain infarct volumes were calculated by summing the volumes of each section and correcting for 
brain swelling, as described
28
. Detailed methods are provided in the supplemental material. 
 
Neurological deficits measurement 
Neurological status was assessed using an adapted 4-point scale test based on Bederson et al.
29
 and was 
graded as previously described
22
: grade 0: normal neurological function; grade 1: forelimb flexion; grade 2: 
circling; grade 3: leaning to the contralateral side at rest; grade 4: no spontaneous motor activity. Motor 
performance was assessed using the RotaRod test. Mice were placed on a rotating rod with increasing speed (4 
– 44 revolutions/min; circumference of the rod: 9 cm) and the latency to fall was measured. The experimental 
trail was ended if the maximum rotation speed was achieved, or if the mouse fell off the rod. Per time point, 3 
test runs per mouse were performed and the best run was included in the statistics. Neurological deficit 
measurements were performed in a blinded way. 
   
Evaluation of long-term effect 
Long-term effect of post-ischaemic in vivo p66
Shc
 silencing on stroke was assessed up to 6 days. The well-
being of mice during the experimental period was determined using a score sheet that was approved by the 
Cantonal Veterinary Office of the Canton of Zurich. This score sheet was used to define survival/death of an 
animal. Death events include spontaneous deaths (4 out of 16 for siScr stroke mice and 3 out of 15 for sip66
Shc
 
stroke mice) and mice which did not fulfil the health evaluation criteria.  
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Evans blue extravasation 
Determination of BBB permeability after MCAO was done by evaluating Evans blue extravasation, as 
described
30
. Detailed methods are provided in the supplemental material. 
 
Immunofluorescence staining  
Frozen brains were cut into 6 µm thick slices on a cryostat (Leica Cm 1900). Immunofluorescent analysis was 
performed as described
31
. Briefly, brain slices were fixed in 4% paraformaldehyde and incubated with primary 
and secondary antibodies. Images were taken using a Leica Dm4000 B microscope. Stained area of claudin-5, 
vascular endothelial (VE)-cadherin, or occludin was measured using ImageJ Software and normalised to the 
total endothelial cell surface (assessed by isolectin B4 staining). Detailed methods are provided in the 
supplemental material. 
 
RNA isolation and reverse transcription 
Total RNA isolation and preparation of cDNA was performed as previously described
26
. Total RNA of PBM, 
or of MCA, was extracted using TRIzol Reagent (Invitrogen). Two µg (MCA), or 1 µg (PBM) of RNA was 
reverse transcribed using Ready-To-Go You-Prime First-Strand Beads (Amersham Biosciences) and first-
strand random cDNA primers pd(N)6 (TaKaRa).  
 
Quantitative real-time PCR  
Determination of p66
Shc
 gene expression was done as previously described
26
. Detailed methods are provided in 
the supplemental material. 
  
Cell culture experiments 
Primary human brain microvascular endothelial cells (HBMEC; Cell Systems) were cultured in EBM-2 
medium supplied with EGM-2 bullet kit (Lonza). Adhering cells (passages 5 to 9) were grown to confluence 
and exposed to hypoxia (0.2% oxygen) for 4 h, followed or not by 4 h of incubation in a normoxic incubator 
9 
 
(reoxygenation). Hypoxia was induced using a gas-controlled glove box (Invivo2 400, Ruskinn 
Technologies). In certain experiments, cells were pre-incubated with apocynin (0.1 mmol/L) (SAFC) for 1 h. 
Thereafter, HBMEC were harvested for measuring superoxide anion (O2
-
) production, nitric oxide (NO) 
bioavailability, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity or immunoblot 
analysis.  
 
siRNA transfection in HBMEC 
HBMEC were incubated with predesigned siRNA targeting p66
Shc
 at final concentration of 25 nmol/L using 
Lipofectamine
®
RNAiMAX Reagent (Invitrogen), as previously described
32
. Detailed methods are provided in 
the supplemental material. 
 
Immunoblotting 
Basilar arteries and cells were lysed in lysis buffer and proteins were separated using SDS-PAGE, as 
previously described
32
. Detailed methods are provided in the supplemental material. 
 
Measurement of O2
-
 production and NO bioavailability  
Electron spin resonance (ESR) spectroscopy was applied to determine O2
−
 production and NO bioavailability, 
as described
27, 32-34
. Detailed methods are provided in the supplemental material. 
 
NADPH oxidase activity  
NADPH oxidase activity was determined indirectly by measuring the ratio of NADP/NADPH using a 
commercially available kit (Abcam), according to the manufacturer’s recommendations. 
 
Statistical analysis 
Statistical analysis for comparison of 2 groups was performed using 2-tailed unpaired Student’s t-test, or 
Mann-Whitney test, when appropriate. For comparison of more than 2 unmatched groups, 1-way analysis of 
10 
 
variance (ANOVA) followed by Bonferroni post hoc test, or Kruskal-Wallis test followed by Dunn’s post hoc 
test, when appropriate, was performed. For comparison of groups with repeated measures, 2-way ANOVA 
followed by Bonferroni post hoc test was applied. Statistical analysis for survival studies was performed using 
Log-rank (Mantel-Cox) test. Pearson’s correlation analysis was used to test the correlation between two 
quantitative variables, and Fisher’s exact test for comparison of categorical data between study subjects. Two-
sided P-values were calculated and P<0.05 denoted a significant difference. Statistical analysis was performed 
using GraphPad Prism
® 
software 5.01.  
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Results 
 
In vivo post-ischaemic silencing of p66
Shc
 reduces lesion volumes and improves functional outcome 
following I/R brain injury  
To study the effect of post-ischaemic p66
Shc
 silencing on stroke, a transient MCAO surgery was performed on 
wt mice to induce I/R brain injury. To analyse p66
Shc
 silencing efficiency in vivo beforehand, p66
Shc
 mRNA 
and protein levels were quantified in cerebral arteries (MCA, and basilar artery, respectively). Intravenous 
injection of siRNA against p66
Shc
 reduced mRNA and protein p66
Shc
 levels within 48 h after injection 
compared to siScr injection (Figure 1A–B). To localise the distribution of the p66Shc siRNA within brain 
cerebral arteries, wt mice were injected with fluorescence dye-labelled p66
Shc
 siRNA (Alexa546-sip66
Shc
). 
Flow cytometry with whole-brain digests revealed a predominant uptake of the siRNA by the brain 
endothelium. We observed that 21.2% of brain endothelial cells (CD45
-
CD31
+
) showed a positive signal for 
Alexa546-tagged p66
Shc 
siRNA (Figure 1F) while only 0.6% of leukocytes (CD45
+
CD31
-
) (Figure 1G) and 
0.2% of other nucleated cells (CD45
-
CD31
-
) (Figure 1H) were positive for the Alexa546 signal. Negative 
control was stained with Hoechst 33342 to label nucleated cells (Figure 1L–N). 
Lesion volumes in sip66
Shc
 and siScr injected stroke mice were quantified with MRI. DWI denoted matching 
baseline lesion sizes in both groups after 45 min of ischaemia and directly upon reperfusion (Figure 2B). At 
48 h post-MCAO both DWI and T2-weighted imaging displayed instead a reduced stroke volume in sip66
Shc
 
stroke mice as compared to siScr stroke mice (Figure 2B–C).  
Neurological deficits after MCAO were assessed using two different tests. Pre-MCAO, both sip66
Shc
 and siScr 
stroke mice showed comparable performance in the RotaRod test and on the 4-point scale test based on 
Bederson et al.
29
 (Figure 2D–E). At 24 h post-MCAO we observed in both groups a reduced latency to fall in 
the RotaRod test. However, at 48 h post-MCAO, sip66
Shc
 stroke mice showed a significant higher persistence 
on the rotating drum compared to siScr stroke mice (Figure 2D). In line with that, neurological deficits 
assessed with the scale test were significantly lower in sip66
Shc
 stroke mice compared to siScr stroke mice at 
48 h post-MCAO (Figure 2E). All sham operated animas displayed normal neurological functions throughout 
the experimental period (Figure 2D and data not shown).  
12 
 
By analysing the impact of p66
Shc
 silencing on stroke up to 6 days, we found an improved survival of sip66
Shc
 
stroke mice as compared to siScr stroke mice (Figure 2F, 31.25% survival for siScr stroke mice vs. 66.66% for 
sip66
Shc
 stroke mice). Survival was assessed in accordance to the health evaluation criteria approved by the 
Cantonal Veterinary Office of the Canton of Zürich; all sham operated animals survived and fulfilled the 
health evaluation criteria (data not shown). 
 
In vivo p66
Shc
 silencing preserves BBB integrity after I/R brain injury 
The BBB plays a critical role for the outcome of stroke
8
, and its permeability can be assessed in vivo by 
quantifying Evans blue extravasation
9, 30
. We tested whether post-ischaemic p66
Shc
 silencing preserves BBB 
permeability after I/R brain injury in mice. Indeed, 48 h post-MCAO p66
Shc
 silencing reduced Evans blue 
extravasation as compared to mice receiving siScr (Figure 3A).  
BBB permeability is regulated by tight and adherens junctional proteins connecting cerebral microvascular 
endothelial cells
35
. Thus, we analysed the integrity of tight and adherens junctions following I/R brain injury 
focusing on claudin-5, occludin, and VE-cadherin. Immunofluorescence staining of claudin-5 on coronal brain 
sections of siScr-treated stroke mice revealed decreased claudin-5-positive stained areas normalised to the 
total endothelial surface (measured by isolectin B4 staining
31, 36
) in the ipsilateral hemisphere compared to the 
contralateral hemisphere (Figure 3B), while this disruption of claudin-5 integrity was not observed in stroke 
mice receiving sip66
Shc
 (Figure 3B). Unlike claudin-5, occludin and VE-cadherin-positive stained areas were 
not changed following I/R brain injury in both experimental groups (data not shown).   
 
Role of p66
Shc
 in H/R in primary HBMEC 
In order to characterise the molecular regulation of claudin-5 by p66
Shc
 and to translate our in vivo murine data 
to human cells, we exposed HBMEC to hypoxia (H) alone, or hypoxia followed by reoxygenation (H/R). 
Exposure of HBMEC to hypoxia neither altered phosphorylation of p66
Shc
 at Ser36, a critical step for its pro-
apoptotic
37
 and pro-oxidant activity
21
, nor total p66
Shc
 protein levels significantly, compared to normoxia 
13 
 
(Figure 4A). By contrast, exposure to H/R increased phosphorylation of p66
Shc
 at Ser36 compared to normoxia 
(Figure 4B). Hypoxia-inducible factor-1 alpha (HIF-1α) protein stabilisation was used as an indicator of 
effective hypoxic conditions (Figure 4A). ROS and NO are critical for endothelial function
20
, and have been 
implicated in vascular permeability
12
. Here, we analysed whether H/R regulates O2
-
 production and NO 
bioavailability, and whether p66
Shc
 mediates these effects. Exposure of HBMEC to H/R led to an increased O2
-
 
production (Figure 4D) and a decreased NO bioavailability (Figure 4E) compared to normoxia. However, 
endothelial NO synthase (eNOS) phosphorylation at both sites studied (Ser1177 and Thr495) and eNOS 
protein expression remained unchanged (Figure 4F–G). Pre-incubation of HBMEC with p66Shc siRNA, but not 
scrambled siRNA, reduced the increased O2
-
 production (Figure 4D) and increased the reduced NO 
bioavailability during H/R (Figure 4E). NADPH oxidase is considered as a major source of vascular O2
-38
, and 
is a downstream target of p66
Shc34, 39
. Moreover, NADPH oxidase was demonstrated to play a dominant role in 
ROS production in brain endothelial cells exposed to H/R
40
. Thus, we investigated whether during H/R 
NADPH oxidase is a source of O2
-
 production downstream of p66
Shc
. Indeed, NADPH oxidase activity was 
increased after exposure to H/R, and returned to control levels after silencing of p66
Shc 
(Figure 4H).  
 
Effect of p66
Shc
 and ROS on claudin-5 in vitro  
HBMEC exposed to H/R exhibited reduced protein levels of claudin-5 compared to normoxia (Figure 5A). In 
contrast, occludin and VE-cadherin protein levels were not affected by exposure to H/R (Figure 5B–C). After 
both, pre-incubation of HBMEC with p66
Shc
 siRNA and with the antioxidant apocynin
41
 claudin-5 levels were 
elevated under H/R condition (Figure 5D–E).   
 
p66
Shc
 gene expression is increased in patients with ischaemic stroke and correlates to neurological 
outcome 
To provide evidence for a role of p66
Shc
 in human ischemic stroke, we analysed p66
Shc
 expression in PBM of 
patients with ischaemic stroke. A total of 27 ischaemic stroke patients and 19 age- and sex-matched, healthy 
control subjects were recruited. Clinical characteristics of both groups did not differ statistically (Table 1). 
14 
 
p66
Shc
 mRNA levels were significantly increased 6 h after initial stroke symptoms (Figure 6A) and returned to 
control levels 24 h thereafter (Figure 6A). Of note, p66
Shc
 gene expression at 6 h was comparable in patients 
with ischaemic stroke regardless of whether they had received thrombolytic treatment or not (Figure 6B). 
p66
Shc
 transcript levels of all study subjects positively correlated with neurological deficits at admission, 
measured according to the NIHSS (Figure 6C). Importantly, while p66
Shc
 gene expression of stroke patients 
which did not receive thrombolytic intervention did not correlate with short-term neurological outcome 
(NIHSS discharge – NIHSS admission) (Figure 6D), it positively correlated in stroke patients treated with 
thrombolysis (Figure 6E). 
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Discussion 
 
In this study we demonstrate for the first time that post-ischemic p66
Shc
 silencing reduces brain injury by 
preserving BBB integrity by preventing claudin-5 level downregulation. The in vivo findings in the mouse 
were translated to human brain microvascular endothelial cells (HBMEC) exposed to H/R where p66
Shc
 was 
phosphorylated at Ser36 leading to the reduction in claudin-5 levels via activation of the NADPH oxidase and 
increased ROS production. Further we show that p66
Shc 
expression is increased in PBM of patients with 
ischaemic stroke within 6 h from onset of symptoms and that p66
Shc 
gene expression correlates to short-term 
neurological outcome.  
In mice, we recently showed that constitutive genetic deletion of p66
Shc
 reduces early stroke size and 
neurological deficits following I/R brain injury
22
. However, the mechanisms of this effect and its clinical 
relevance remained elusive. Furthermore, the use of constitutive knockout animals only serves as a proof-of-
principle and does not allow delineation of therapeutic time windows as required in the clinical setting. In 
contrast, RNA interference (RNAi)-based strategies allow to modify the expression of a certain target at the 
post-transcriptional level, thus making it therapeutically interesting
42
. Indeed, several RNAi-based strategies 
are under investigation in clinical trials
43
. Here, we used a clinically relevant experimental setup with siRNA 
delivery upon reperfusion to reduce p66
Shc
 levels. Reperfusion of an occluded vessel allows reoxygenation of 
the ischaemic area which promotes recovery of penumbral areas
44
. Nevertheless paradoxically, re-introduction 
of oxygen in a previously ischaemic area also causes a surge in free radical generation
11
 which interferes with 
the recovery processes. Indeed, we demonstrate here that silencing of the pro-oxidant p66
Shc
 after the 
ischaemic episode and upon reperfusion, as it would be the case in stroke patients presenting at the emergency 
room undergoing thrombolytic treatment, reduces lesion volume, improves neurological function and 
increases survival. These data highlight the potential of p66
Shc
 as novel therapeutic target in stroke patients 
undergoing thrombolysis. 
Given the key role of BBB permeability in determining stroke outcome
6
, we characterised its integrity by 
analysing Evans blue extravasation, a known indicator for vascular leakage
9, 30, 31, 45
. Indeed, and in line with 
the improved stroke outcome in the sip66
Shc
 stroke mice, BBB disruption was blunted after p66
Shc
 silencing 
compared to control mice. Cerebral microvascular endothelial cells connected via tight and adherens 
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junctional proteins make up the BBB
7
. A disruption of this tightly regulated structure is known to occur in I/R 
brain injury and is responsible for vascular leakage and in turn oedema formation
9-11
. To investigate the 
molecular mechanisms by which p66
Shc
 preserves BBB integrity after I/R brain injury, we focused in vivo as 
well as in vitro on claudin-5, occludin and VE-cadherin, three major junctional proteins
7
. Consistently, we 
found less reduction in claudin-5 levels after silencing of p66
Shc
. In contrast, occludin and VE-cadherin levels 
remained unaltered in both experimental settings. Our data obtained on murine as well as primary human cells 
indicate that p66
Shc
 mediates BBB disruption by acting specifically on claudin-5 rather than occludin and VE-
cadherin.  
To characterise the molecular regulation of claudin-5 by p66
Shc
, we exposed primary human brain 
microvascular endothelial cells (HBMEC) to H/R, to mimic in vivo settings. Exposure of HBMEC to H/R, but 
not to hypoxia, increased phosphorylation of p66
Shc
 at Ser36 confirming previous data in renal tubular 
epithelial cells
46
. Together with our in vivo data these results suggest that p66
Shc
 is mainly involved in 
mediating its deleterious effects during reperfusion, rather than during ischaemia. Endothelial ROS production 
and NO bioavailability are both critical for I/R-induced alteration in BBB permeability and stroke outcome
12, 
47
 and ROS are known to influence claudin-5 levels in brain endothelial cells
48
. Here, we demonstrate in vitro 
evidence that endothelial p66
Shc
 silencing in H/R preserves NO bioavailability reduces NADPH oxidase 
activation and decreases ROS generation thus blunting the reduction in claudin-5 levels. This pathway may be 
also relevant in vivo.  
To study p66
Shc
 gene regulation in stroke patients, we performed proof-of-principle experiments assessing its 
expression in peripheral blood monocytes (PBM) of acute ischaemic stroke patients. Although it would be of 
particular interest and relevance to elucidate the role of cerebrovascular p66
Shc
 in stroke patients, sample 
collection in humans would prove extremely difficult thus, we selected PBM since those are easily obtainable 
from whole-blood and could still give us interesting insights into gene expression changes. Here we found that 
p66
Shc
 mRNA levels were increased 6 h after initial stroke symptoms and then returned to basal levels at 24 h. 
Moreover, p66
Shc
 expression at 6 h correlated to short-term neurological outcome (delta NIHSS) in stroke 
patients. Interestingly, delta NIHSS correlated to p66
Shc
 expression only in patients undergoing thrombolysis, 
but not in those without. Although thrombolysis is known to improve neurological outcome after stroke
5
, it is 
17 
 
also associated with early reperfusion-induced BBB damage
49
 which is known to be mediated by ROS and 
affects stroke outcome
6
. An increased vascular leakage also favours the accumulation of blood circulating 
cells in brain tissue thus causing tissue damage via production of free radicals
11, 50
. This could explain why the 
correlation between neurological outcome and p66
Shc
 expression is found only in thrombolytic patients where 
monocytic p66
Shc
-induced ROS production and the consequent damage is likely more pronounced. In contrast, 
in patients not undergoing thrombolysis, the role of reperfusion-induced ROS-dependent injury is less 
prominent and thus neurological damage is less likely to be dependent on p66
Shc
-mediated ROS.  
In summary, the present study sets the stage for follow up clinical studies aimed at assessing the potential for 
p66
Shc
 to become a novel therapeutic target as an adjunct of thrombolysis for the management of acute 
ischaemic stroke. 
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Figure Legends 
Figure 1 In vivo silencing of p66
Shc
. (A) Quantitative real-time PCR reveals reduced p66
Shc
 levels in middle 
cerebral artery homogenates 24 h (n=5-6) and 48 h (n=7-8) after p66
Shc
 siRNA injection compared to 
scrambled siRNA injection (siScr). Data are expressed as mean ± s.e.m. * P<0.05 for sip66
Shc
 vs. siScr. (B) 
Immunoblot analysis confirms silencing of p66
Shc
 in basilar arteries within 48 h after p66
Shc
 siRNA injection 
(representative immunoblot of at least 5 animals per group). (C–N) Flow cytometry analysis of brain single 
cell suspensions 24 h after injection of Alexa546-sip66
Shc
 (upper panel) as compared to negative control 
(lower panel). Singlets (C; I) with nuclei (D; J) were plotted in a dot plot of APC (CD45) versus 
AlexaFluor488 (CD31) to distinguish endothelial cells (CD45
-
CD31
+
), leukocytes (CD45
+
CD31
-
), as well as 
other cell types (CD45
-
CD31
-
) (E; K). Histogramms show Alexa546-fluorescence representing content of 
Alexa546-sip66
Shc
 in endothelial cells (F; L), leukocytes (G; M) and other cell types (H; N).  
 
Figure 2 Impact of post-ischaemic in vivo p66
Shc
 silencing on stroke outcome. (A) Schematic of experimental 
study design. Upon reperfusion, specific siRNA against p66
Shc
 is injected intravenously in wt mice, and 
development of lesion and functional deficits were characterised. (B–C) Both, DWI and T2-weighted imaging 
denote reduced lesions in sip66
Shc
 stroke mice (DWI: n=5; T2: n=6) compared to siScr stroke mice (n=7) at 48 
h post-MCAO. (D–E) Evaluation of neurological deficits by using the RotaRod test and a 4-point scale test 
based on Bederson et al.
28
. Both neurological tests demonstrate less neurological deficits in the sip66
Shc
 stroke 
group (n=9) compared to the siScr stroke group (RotaRod: n=7; Bederson: n=8). All sham operated animals 
show normal neurological function throughout the experimental period (n=5-6). (F) Post-ischemic silencing of 
p66
Shc
 increases survival of mice after stroke (n=15-16). Data are expressed as mean ± s.e.m. * P<0.05, ** 
P<0.01 for sip66
Shc
 stroke vs. siScr stroke.     
 
Figure 3 p66
Shc
 mediates BBB disruption after I/R brain injury. (A) Assessment of BBB impairment. p66
Shc
 
silenced mice (n=6) show less Evans blue extravasation compared to siScr stroke mice (n=5) at 48 h of 
reperfusion. (B) Representative fluorescence microscopy images of claudin-5 and isolectin B4 (endothelial 
marker) stained brain sections. Following I/R brain injury, claudin-5-positive stained area normalised to the 
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total endothelial surface is reduced in the ipsilateral hemisphere compared to the contralateral hemisphere in 
siScr stroke mice (n=5), but not in sip66
Shc
 stroke mice (n=5). Scale bar, 35 µm. Data are presented as mean ± 
s.e.m. * P<0.05 for siScr stroke ipsilateral vs. siScr stroke contralateral; ** P<0.01 for sip66
Shc
 stroke vs. siScr 
stroke. 
 
Figure 4 p66
Shc
 mediates H/R-induced damage of HBMEC. (A) p66
Shc
 activation remains unchanged after 
exposure of HBMEC to hypoxia compared to normoxia (n=8). HIF-1α stabilization is used as an indicator for 
effective hypoxic condition. (B) Hypoxia followed by reoxygenation increases phosphorylation of p66
Shc
 at 
Ser36 compared to normoxia (n=6). (C) Representative immunoblot of p66
Shc
 silencing in vitro. Pre-
incubation of HBMEC with p66
Shc
 siRNA selectively reduces p66
Shc
 levels, without affecting the levels of the 
two other Shc isoforms p52
Shc
 and p46
Shc
. (D) H/R leads to an increased O2
-
 production (n=12-13) that is 
blunted after silencing of p66
Shc
 (n=7-13). (E) HBMEC exposed to H/R show a reduced NO bioavailability 
(n=12) that is elevated after p66
Shc
 silencing (n=6-12). (F–G) H/R does not alter phosphorylation of eNOS at 
both sites studied (Ser1177 and Thr495) and eNOS protein expression compared to normoxia (n=7). (H) Pre-
incubation of HBMEC with p66
Shc
 siRNA reduces H/R-increased NADPH oxidase activity (n=11). Data are 
expressed as mean ± s.e.m. * P<0.05, ** P<0.01, *** P<0.001 for H/R vs. normoxia; 
#
 P<0.05, 
# #
 P<0.01 for 
H/R with sip66
Shc
 vs. H/R.  
 
Figure 5 Effect of p66
Shc
 silencing and ROS on H/R-decreased claudin-5 expression. (A) Immunoblot 
analysis reveals decreased claudin-5 protein levels after exposure of HBMEC to H/R (n=7), but not of 
occludin (n=5) (B) and VE-cadherin (n=7) (C). Pre-incubation with p66
Shc
 siRNA (n=7) (D), or apocynin (0.1 
mmol/L) (n=6) (E), increases claudin-5 levels under H/R condition. Data are presented as mean ± s.e.m. ** 
P<0.01, *** P<0.001 for H/R vs. normoxia; 
#
 P<0.05, 
# #
 P<0.01 for H/R with sip66
Shc
 or apocynin vs. H/R. 
 
Figure 6 p66
Shc
 gene expression in PBM of ischaemic stroke patients. (A) Real-time PCR determined 
increased p66
Shc
 mRNA levels in stroke patients 6 h (n=27), but not 24 h (n=16) after initial stroke symptoms 
compared to the levels of control subjects (n=19). Data are expressed as mean ± s.e.m. (B) p66
Shc
 gene 
expression 6 h after initial stroke symptoms was determined in subgroups of stroke patients according as they 
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did (t-PA), or did not (w/o t-PA) receive thrombolytic treatment. Values from controls are also shown for 
comparisons. p66
Shc
 mRNA levels are not different between both stroke subgroups (w/o t-PA: n=13; t-PA: 
n=14). Both subgroups show higher p66
Shc
 levels compared to controls. Data are expressed as mean ± s.e.m. 
(C) Correlation between p66
Shc
 gene expression and NIHSS at admission of all study subjects (n=46). (D–E) 
Correlation analysis of p66
Shc
 transcripts and deltaNIHSS (NIHSS discharge – NIHSS admission) in w/o t-PA 
patients (n=13) and in t-PA patients (n=14). For (C–E) linear regression trend lines are illustrated. *** 
P<0.001. NIHSS, National Institutes of Health Stroke Scale; t-PA, tissue plasminogen activator. 
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Text Tables 
 
Table 1 Characteristics of clinical study population. Clinical characteristics of controls and stroke patients do 
not differ statistically. Subgroup analysis shows statistically significant differences in age and NIHSS at 
discharge between patients treated with thrombolysis and patients which did not receive thrombolysis. Age is 
given as mean (with ranges) and NIHSS is expressed as mean ± SD. TIA, transient ischaemic attack; tPA, 
tissue plasminogen activator; TACI, total anterior circulation infarct; PACI, partial anterior circulation infarct; 
LACI, lacunar infarct; POCI, posterior circulation infarct; TOAST, Trial of ORG 10172 in Acute Stroke 
Treatment; NIHSS, National Institutes of Health Stroke Scale. 
 
 
 
 
 
 
